Mouse IgG2a k Isotype Control – Purified Functional Grade, GOLD

Unknown

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

CODEX®, CyTOF®

Mouse Anti-Human HLA-DR (Clone L243) recognizes/reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross-react with HLA-DP and HLA-DQ. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

The HLA-DR antigen is present on B-lymphocytes, activated T-lymphocytes and activated natural killer (NK) lymphocytes. This antigen is also expressed on monocytes, macrophages, human progenitor cells and B-cell lymphomas.

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD (heavy) chain & a 27 kD (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, and dendritic cells. HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Clone L243 binds a conformational epitope on HLA-DRα which depends on the correct folding of the αβ heterodimer.

CD3/TCR, CD4

Peptide presentation

Information on Uniprot.org

1. Wakita, H. et al. (1995) J Invest Dermatol 105:536-542. Article Link
2. Bellone, CJ. et al. (1996) J Clin Invest. 97(10):2324-31. PubMed
3. Ikeda Y. et al. (2003) Blood.101(2):621-3. Article Link
4. Lokhorst, HM et al. (2003) Clin Exp Immunol 131:340–346PubMed
5. Wright, TM et al. (2000) J Immunol.164(12):6138-46.Article Link
6. Bloem, AC et al.(2005) Br J Haematol.128(1):73-81.PubMed
7. Wright, TM et al. (1995) J Clin Invest. 96(1):586-96. PubMed
8. Nishikawa, Takeji et al. (2000) J Investigative Dermatology 114(1): 88-94. PubMed
9. Wright, TM et al. (2001) Arthritis Rheum. 44(7):1654-9. PubMed
10. Lampson, L. A. et al. (1980) J. Immunol. 125:393
11. Yu, D. T. Y. et al. (1980) J. Exp. Med. 151:91
12. Warnke, R. et al. (1980) N. Eng. J. Med. 303:293
13. Wilkinson, KA et al. (2005) Infect Immun. 74(5):2991-8